Daily Newsletter

16 July 2024

Daily Newsletter

16 July 2024

AstraZeneca completes Amolyt Pharma acquisition

The move strengthens AstraZeneca’s late-stage pipeline within its Alexion rare disease division.

Archana Rani July 16 2024

AstraZeneca has closed the acquisition of Amolyt Pharma, a company specialising in treatments for rare endocrine diseases.

The deal between the parties was announced in March 2024.

AstraZeneca made a $1.05bn payment for all outstanding shares of Amolyt Pharma, free of cash and debt.

The transaction includes an upfront payment of $800m and an additional $250m contingent upon reaching a particular regulatory milestone.

The strategic move strengthens AstraZeneca's late-stage pipeline within its Alexion rare disease division and adds the investigational therapeutic peptide eneboparatide (AZP-3601) to its bone metabolism portfolio.

Eneboparatide is in Phase III development for hypoparathyroidism and binds to the parathyroid hormone (PTH) receptor with high affinity.

Hypoparathyroidism is a rare condition defined by PTH deficiency that results in low calcium and elevated levels of phosphorus in the blood.

Clinical manifestations of this condition impact tissues and organ systems, specifically kidneys and bone.

Eneboparatide is a subcutaneous parathyroid hormone receptor 1 agonist for the treatment of hypoparathyroidism.

Its therapeutic goals are to regulate serum calcium levels, manage hypoparathyroidism symptoms, reduce urine calcium excretion and potentially prevent kidney function decline and chronic kidney disease.

Its short plasma half-life may help normalise bone turnover and maintain bone health.

Another candidate in Amolyt’s pipeline is AZP-3813, a peptide growth hormone receptor antagonist being developed as a potential add-on to somatostatin analogues for the treatment of acromegaly, a condition associated with abnormally high secretion of growth hormone.

AstraZeneca’s rare disease portfolio generated $7.76bn in global sales in 2023, as reported in the company’s fourth-quarter financial reports.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close